The appearance of angioid streaks (AS) was initially described by Doyne in 1889 as irregular and radiating lines extending from the optic nerve to the peripheral retina. They are found in eyes with retinal hemorrhages after blunt trauma. In a recent UK investigation, the annual incidence of AS-associated CNV is estimated ~ 0.057 cases per 100,000 individuals, confirming the rarity of this condition¹. AS represent discrete irregular breaks in Bruch's membrane and are often associated with atrophic changes of the overlying retinal pigment epithelium (RPE) and calcific degeneration. The most common and significant complication of AS is the development of CNV, which is often bilateral and occurs in 72–86% of eyes with AS. Significant improvement in visual outcomes has been found after using anti-VEGF therapy, however, geographic atrophy (GA) contributes to visual loss in patients with AS. There is an opportunity for AG-73305, which has both anti-VEGF and anti-integrin activity, to benefit patients with AS.